Skip to main content

Advertisement

SpringerLink
Log in

Phosphorylated mTOR Expression is Associated with Poor Prognosis for Patients with Esophageal Squamous Cell Carcinoma

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The mammalian target of rapamycin (mTOR) plays central roles in the regulation of cell growth and proliferation by monitoring nutrient availability, cellular energy level, oxygen level, and mitogenic signals. The aberrant activation of mTOR in relation to clinical outcome has been reported in several types of cancers. mTOR is increasingly important as a potential target for anticancer therapy. Nonetheless, a prognostic feature of mTOR activation in esophageal squamous cell carcinoma (ESCC) remains uncertain.

Materials and Methods

First, in order to validate phospho-specific mTOR antibody (Ser2448), phosphorylated mTOR (p-mTOR) expression levels in five ESCC cell lines under cultural conditions with or without everolimus (mTOR inhibitor, also known as RAD001) were evaluated by in vitro immunohistochemistry and immunoblotting. Second, we examined p-mTOR expression by immunohistochemistry using 143 resected ESCC specimens. Prognostic significance of p-mTOR expression was examined by Cox regression and Kaplan–Meier analyses.

Results

Among 143 patients, 71 (49.7%) were classified into p-mTOR-positive and 72 (50.3%) were classified into p-mTOR-negative. Compared with p-mTOR-negative patients, p-mTOR-positive patients experienced high overall mortality [hazard ratio (HR) 2.44; 95% confidence interval (CI), 1.24–4.83; P = 0.008], which persisted in multivariate analysis (multivariate HR 2.92; 95% CI, 1.48–5.78; P = 0.002). A similar finding was observed for esophageal cancer-specific mortality. p-mTOR expression was not related with any clinical or pathologic variables including age, sex, tumor location, histological grading, operative procedure, T classification (tumor invasion), or lymph-node metastasis.

Conclusions

p-mTOR overexpression was independently associated with poor prognosis in ESCC, supporting the potential for mTOR as a therapeutic target for ESCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.

    Article  PubMed  CAS  Google Scholar 

  2. Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. J Clin Oncol. 2007;25:4110–7.

    Article  PubMed  CAS  Google Scholar 

  3. Wouters MW, Karim-Kos HE, le Cessie S, Wijnhoven BP, Stassen LP, Steup WH, et al. Centralization of esophageal cancer surgery: does it improve clinical outcome? Ann Surg Oncol. 2009;16:1789–98.

    Article  PubMed  CAS  Google Scholar 

  4. Brucher BL, Swisher SG, Konigsrainer A, Zieker D, Hartmann J, Stein H, et al. Response to preoperative therapy in upper gastrointestinal cancers. Ann Surg Oncol. 2009;16:878–86.

    Article  PubMed  Google Scholar 

  5. Nakamura T, Ota M, Narumiya K, Sato T, Ohki T, Yamamoto M, et al. Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. Ann Surg Oncol. 2008;15:2451–7.

    Article  PubMed  Google Scholar 

  6. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007;8:545–53.

    Article  PubMed  Google Scholar 

  7. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424–30.

    Article  PubMed  CAS  Google Scholar 

  8. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–84.

    Article  PubMed  CAS  Google Scholar 

  9. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6:729–34.

    Article  PubMed  CAS  Google Scholar 

  10. Herberger B, Puhalla H, Lehnert M, Wrba F, Novak S, Brandstetter A, et al. Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res. 2007;13:4795–9.

    Article  PubMed  CAS  Google Scholar 

  11. Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res. 2009;15:1821–9.

    Article  PubMed  CAS  Google Scholar 

  12. Murayama T, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, et al. Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Cancer. 2009;100:782–8.

    Article  PubMed  CAS  Google Scholar 

  13. Zhou L, Huang Y, Li J, Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol. 2009 [Epub ahead of print].

  14. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27:2278–87.

    Article  PubMed  CAS  Google Scholar 

  15. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4:335–48.

    Article  PubMed  CAS  Google Scholar 

  16. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res. 2007;13:3109–14.

    Article  PubMed  CAS  Google Scholar 

  17. Dutcher JP. Mammalian target of rapamycin inhibition. Clin Cancer Res. 2004;10:6382S–7S.

    Article  PubMed  CAS  Google Scholar 

  18. Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res. 2009;15:5404–13.

    Article  PubMed  CAS  Google Scholar 

  19. Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res. 2007;13:4261–70.

    Article  PubMed  CAS  Google Scholar 

  20. Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res. 2009;15:1612–22.

    Article  PubMed  CAS  Google Scholar 

  21. Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res. 2007;67:2408–13.

    Article  PubMed  CAS  Google Scholar 

  22. Baba Y, Iyama K, Ikeda K, Ishikawa S, Hayashi N, Miyanari N, et al. The expression of type IV collagen alpha6 chain is related to the prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2008;15:555–65.

    Article  PubMed  Google Scholar 

  23. Baba Y, Iyama KI, Hirashima K, Nagai Y, Yoshida N, Hayashi N, et al. Laminin-332 promotes the invasion of oesophageal squamous cell carcinoma via PI3 K activation. Br J Cancer. 2008;98:974–80.

    Article  PubMed  CAS  Google Scholar 

  24. Hiyoshi Y, Watanabe M, Hirashima K, Karashima R, Sato N, Imamura Y, et al. p12CDK2-AP1 is associated with tumor progression and a poor prognosis in esophageal squamous cell carcinoma. Oncol Rep. 2009;22:35–9.

    PubMed  CAS  Google Scholar 

  25. Baba Y, Iyama K, Honda S, Ishikawa S, Miyanari N, Baba H. Cytoplasmic expression of type VII collagen is related to prognosis in patients with esophageal squamous cell carcinoma. Oncology. 2006;71:221–8.

    Article  PubMed  CAS  Google Scholar 

  26. Boone J, Ten Kate FJ, Offerhaus GJ, van Diest PJ, Rinkes IH, van Hillegersberg R. mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy? J Clin Pathol. 2008;61:909–13.

    Article  PubMed  CAS  Google Scholar 

  27. Yoshioka A, Miyata H, Doki Y, Yasuda T, Yamasaki M, Motoori M, et al. The activation of Akt during preoperative chemotherapy for esophageal cancer correlates with poor prognosis. Oncol Rep. 2008;19:1099–107.

    PubMed  CAS  Google Scholar 

  28. Anagnostou VK, Bepler G, Syrigos KN, Tanoue L, Gettinger S, Homer RJ, et al. High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma. Clin Cancer Res. 2009;15:4157–64.

    Article  PubMed  CAS  Google Scholar 

  29. Noske A, Lindenberg JL, Darb-Esfahani S, Weichert W, Buckendahl AC, Roske A, et al. Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol Rep. 2008;20:1409–17.

    PubMed  CAS  Google Scholar 

  30. Engelman JA. Targeting PI3 K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550–62.

    Article  PubMed  CAS  Google Scholar 

  31. Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol. 2004;22:4217–26.

    Article  PubMed  CAS  Google Scholar 

  32. Luo J, Manning BD, Cantley LC. Targeting the PI3 K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4:257–62.

    Article  PubMed  CAS  Google Scholar 

  33. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501.

    Article  PubMed  CAS  Google Scholar 

  34. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8:627–44.

    Article  PubMed  CAS  Google Scholar 

  35. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5:671–88.

    Article  PubMed  CAS  Google Scholar 

  36. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O’Reilly T, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005;120:747–59.

    Article  PubMed  CAS  Google Scholar 

  37. Rupertus K, Dahlem C, Menger MD, Schilling MK, Kollmar O. Rapamycin inhibits hepatectomy-induced stimulation of metastatic tumor growth by reduction of angiogenesis, microvascular blood perfusion, and tumor cell proliferation. Ann Surg Oncol. 2009;16:2629–37.

    Article  PubMed  Google Scholar 

  38. Campone M, Levy V, Bourbouloux E, Berton Rigaud D, Bootle D, Dutreix C, et al. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer. 2009;100:315–21.

    Article  PubMed  CAS  Google Scholar 

  39. Tanaka C, O’Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol. 2008;26:1596–602.

    PubMed  CAS  Google Scholar 

  40. Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009;27:193–8.

    Article  PubMed  CAS  Google Scholar 

  41. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26:4311–8.

    Article  PubMed  Google Scholar 

  42. Ekshyyan O, Rong Y, Rong X, Pattani KM, Abreo F, Caldito G, et al. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther. 2009;8:2255–65.

    Article  PubMed  CAS  Google Scholar 

  43. Jimeno A, Kulesza P, Wheelhouse J, Chan A, Zhang X, Kincaid E, et al. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer. 2007;96:952–9.

    Article  PubMed  CAS  Google Scholar 

  44. Nathan CO, Amirghahari N, Rong X, Giordano T, Sibley D, Nordberg M, et al. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res. 2007;67:2160–8.

    Article  PubMed  CAS  Google Scholar 

  45. Khariwala SS, Kjaergaard J, Lorenz R, Van Lente F, Shu S, Strome M. Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII). Laryngoscope. 2006;116:814–20.

    Article  PubMed  Google Scholar 

  46. Hou G, Xue L, Lu Z, Fan T, Tian F, Xue Y. An activated mTOR/p70S6 K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett. 2007;253:236–48.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

    Kotaro Hirashima MD, Yoshifumi Baba MD, PhD, Masayuki Watanabe MD, PhD, Ryu-ichi Karashima MD, Nobutaka Sato MD, Yu Imamura MD, PhD, Yukiharu Hiyoshi MD, PhD, Yohei Nagai MD, Naoko Hayashi MD, PhD & Hideo Baba MD, PhD

  2. Department of Surgical Pathology, Kumamoto University Hospital, Kumamoto, Japan

    Kotaro Hirashima MD, Yoshifumi Baba MD, PhD & Ken-ichi Iyama MD, PhD

Authors
  1. Kotaro Hirashima MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshifumi Baba MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masayuki Watanabe MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ryu-ichi Karashima MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nobutaka Sato MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yu Imamura MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yukiharu Hiyoshi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yohei Nagai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Naoko Hayashi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ken-ichi Iyama MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hideo Baba MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideo Baba MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hirashima, K., Baba, Y., Watanabe, M. et al. Phosphorylated mTOR Expression is Associated with Poor Prognosis for Patients with Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 17, 2486–2493 (2010). https://doi.org/10.1245/s10434-010-1040-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-010-1040-1

Keywords

Search

Navigation